FDA OKs Merck treatment for babies with HIV

The FDA has approved Merck's (MRK -0.9%) Isentress oral formulation for treating HIV-1 infection in babies who are four weeks old and above when used with other therapies, which appears to increase the chances of success.

Merck expects the formulation to be available in the U.S. in Q3. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs